Tempus AI今日盘前股价大涨5.11%，引起了市场的广泛关注。
消息面上，公司近期接连释放多项利好。首先，Tempus AI宣布与吉利德科学签署扩展的多年期合作协议，吉利德将获得其AI驱动的Lens平台企业级访问权限，在多个适应症中更广泛使用去标识化的多模态数据集，以支持肿瘤学管线开发。其次，公司联合Predicta Biosciences推出了联合品牌全基因组测序检测产品Geno Predicta，用于血液系统恶性肿瘤综合基因组分析及残留病监测。此外，旗下Tempus Pixel正式获批在美国商业使用，构成了重要的监管里程碑。这些产品与合作进展的叠加，持续提振了市场对公司的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.